## Table of Contents

### BREAKING ADVANCES

6793  
**Highlights from Recent Cancer Literature**

### REVIEWS

6795  
**Discovery of IDO1 Inhibitors: From Bench to Bedside**
George C. Prendergast, William P. Malachowski, James B. DuHadaway, and Alexander J. Müller

6812  
**Emerging Role of CRISPR/Cas9 Technology for MicroRNAs Editing in Cancer Research**
Guillermo Aquino-Jarquin

### PRIORITY REPORT

6818  
**RUNX1 Upregulation by Cytotoxic Drugs Promotes Apoptosis**
Daniel Speidel, Jasmin Wellbrock, and Melissa Abas

### MOLECULAR AND CELLULAR PATHOBIOLOGY

6825  
**PP2A Inactivation Mediated by PPP2R4 Haploinsufficiency Promotes Cancer Development**
Ward Sents, Bob Meesesen, Petar Kalev, Enrico Radaelli, Xavier Sagart, Eline Miermans, Dorien Haesen, Caroline Lambrecht, Mieke Dewerchin, Peter Carmeliet, Jukka Westermarck, Anna Sablina, and Veerle Janssens

6838  
**SKP2 Activation by Thyroid Hormone Receptor β2 Bypasses Rb-Dependent Proliferation in Rb-Deficient Cells**
Xiaoliang Xu, Zhengke Li, Aihong Liu, Xianqun Fan, Dan-ning Hu, Dong-Lai Qi, David W. Chitty, Renbing Jia, Jianping Qui, Justin Q. Wang, Jake Sharaf, Jun Zou, Rebecca Weiss, Hongyan Huang, Walter J. Joseph, Lily Ng, Richard Rosen, Binghui Shen, Mark W. Reid, Douglas Forrest, David H. Abramson, Samuel Singer, David Cobrinik, and Suresh C. Jhanwar

6851  
**STK33 Promotes Growth and Progression of Pancreatic Cancer as a Critical Downstream Mediator of HIF1α**
Fanyang Kong, Xiangyu Kong, Yiqi Du, Ying Chen, Xuan Deng, Jianwei Zhu, Jiawei Du, Lei Li, Zhiliang Jia, Dacheng Xie, Zhaoshen Li, and Keping Xie

6863  
**PAGE4 Undergoes an Oncogenic Alternative Splicing Switch in Cancer**
Frédéric Couture, Robert Sabbagh, Anna Kwiatkowski, Roxane Desjardins, Simon-Pierre Guay, Luigi Bouchard, and Robert Day

6880  
**Protein Acyltransferase DHHC3 Regulates Breast Tumor Growth, Oxidative Stress, and Senescence**
Chandan Sharma, Hong-Xing Wang, Qinglin Li, Konstantin Knoblisch, Emily S. Reisenbichler, Andrea L. Richardson, and Martin E. Hemler

6891  
**Subtype-Specific Tumor-Associated Fibroblasts Contribute to the Pathogenesis of Uterine Leiomyoma**
Xin Wu, Vanida A. Serna, Justin Thomas, Wenan Qiang, Michael L. Blumenfeld, and Takeshi Kurita

6902  
**miR-6883 Family miRNAs Target CDK4/6 to Induce G1 Phase Cell-Cycle Arrest in Colon Cancer Cells**
Amriti R. Lulla, Michael J. Slifker, Yan Zhou, Avital Lev, Margret B. Einarsson, David T. Dicker, and Wafik S. El-Deiry

---

December 15, 2017 • Volume 77 • Number 24

American Association for Cancer Research
Conflicts: Targeting the AGC kinase SGK1 along with AKT inhibits proliferation of neoplastically transformed cells more efficiently than blocking both PI3K and AKT, a finding with potential implications for treating tumors with increased PI3K signaling.

NFκB Promotes Ovarian Tumorigenesis via Classical Pathways That Support Proliferative Cancer Cells and Alternative Pathways That Support ALDH+ Cancer Stem–like Cells

Mitochondrial Haplotype Alters Mammary Cancer Tumorigenicity and Metastasis in an Oncogenic Driver–Dependent Manner

Blocking Myristoylation of Src Inhibits Its Kinase Activity and Suppresses Prostate Cancer Progression

New Generation Nanomedicines Constructed from Self-Assembling Small-Molecule Prodrugs Alleviate Cancer Drug Toxicity

Genomic Activation of PPARG Reveals a Candidate Therapeutic Axis in Bladder Cancer

H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma

This report offers an innovative scalable strategy for generating stable and better tolerated cytotoxic nanomedicines.

This paper presents a mechanistic rationale for a strategy to improve the response of esophageal cancers to radiotherapy, which tends to be resistant to this modality.

These results offer a preclinical proof of concept for a selective FGFR-4 inhibitor as a candidate therapeutic agent to treat liver cancers that exhibit increased expression of FGF19, including in effective combinations with the CDK4/6 inhibitor palbociclib.
A Synthetic CD8α:MyD88 Coreceptor Enhances CD8+ T-cell Responses to Weakly Immunogenic and Lowly Expressed Tumor Antigens

Sabina Kaczanowska, Ann Mary Joseph, Jitao Guo, Alexander K Tsai, Jackline Joy Lasola, Kenisha Younger, Yujit Zhang, Cruz Velasco Gonzales, and Eduardo Davila

Précis: These findings highlight a unique method to lower the T-cell receptor recognition threshold to any antigen and the ability to reshape the tumor environment to one that favors antitumor immunity independent of HLA type.

Distinct Angiogenic Changes during Carcinogenesis Defined by Novel Label-Free Dark-Field Imaging in a Hamster Cheek Pouch Model

Fangyao Hu, Hannah Martin, Amy Martinez, Jeffrey Everitt, Alaatinn Ekanli, Walter T. Lee, Mark Dewhirst, and Nimmi Ramanujam

Précis: A novel method to image neovascularization allows for extraction and analysis of specific vascular features for the purposes of cancer screening and prevention.
[18F]Fluorothymidine PET Informs the Synergistic Efficacy of Capecitabine and Trifluridine/Tipiracil in Colon Cancer
Seog-Young Kim, Jin Hwa Jung, Haeng Jung Lee, Hyunsu Soh, Sang Ju Lee, Seung Jun Oh, Sun Young Chae, Jai Hyuen Lee, Seung Jin Lee, Yong Sang Hong, Tae Won Kim, and Dae Hyuk Moon

Précis: These findings suggest that any inhibitor with a primary target mechanism of thymidylate synthase inhibition may be combined with trifluridine/tipiracil in colon cancer and possibly other cancer types.

LETTER TO THE EDITOR

A Systems Approach to Prostate Cancer Classification—Letter
Elin Thysell, Erik Bovinder Ylitalo, Emma Jernberg, Anders Bergh, and Pernilla Wikström

A Systems Approach to Prostate Cancer Classification—Response
Sungyong You and Michael R. Freeman

CORRECTION

Correction: JARID1B Enables Transit between Distinct States of the Stem-like Cell Population in Oral Cancers

Acknowledgment to Reviewers

ABOUT THE COVER

Mitochondrial polymorphisms are associated with defining human clades (races) and with susceptibility to mammary tumor development and metastasis. Brinker and colleagues show that metastatic efficiency changes with different mitochondrial haplotypes in an oncogenic driver-dependent manner. Vimentin is a marker of an epithelial-mesenchymal transition, a process that is often associated with tumor invasion and metastasis. Unexpectedly, no effect on vimentin immunohistochemical staining was observed in HER2-driven mammary tumors despite changes in metastatic efficiency. For details, see article by Brinker and colleagues on page 6941.
Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/77/24

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://cancerres.aacrjournals.org/content/77/24.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.